Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2005
12/29/2005US20050287203 Formulation comprising testosteron undecanoate and castor oil
12/29/2005US20050287202 Compound
12/29/2005US20050287201 Method for delivery of pharmaceuticals for treating or preventing presbyopia
12/29/2005US20050287200 Phospholipid gel compositions for drug delivery and methods of treating conditions using same
12/29/2005US20050287199 Therapeutic micro nutrient composition for lipolysis and drug delivery
12/29/2005US20050287198 Phospholipid gel compositions for drug delivery and methods of treating conditions using same
12/29/2005US20050287197 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x
12/29/2005US20050287196 Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release
12/29/2005US20050287195 Transdermal drug delivery systems
12/29/2005US20050287194 Permeation enhancing compositions for anticholinergic agents
12/29/2005US20050287189 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms
12/29/2005US20050287188 Controlled release bioactive agent delivery device
12/29/2005US20050287185 Extended release oxybutynin formulation
12/29/2005US20050287181 A mixture of propylene carbonate and glycerol formal in a ratio of 90:10-10:90 containing hydroxypropylmethylcellulose, a phospholipid and a fungicide; time-released agent; sustained'release; veterinary medicine; sustained release; topical, otic, and ophthalmic
12/29/2005US20050287180 Phospholipid compositions and methods for their preparation and use
12/29/2005US20050287179 Use of ethyl lactate as an excipient for pharmaceutical compositions
12/29/2005US20050287178 Diagnosis and treatment of heavy gallbladder densities
12/29/2005US20050287177 Pharmaceutical compositions
12/29/2005US20050287175 modulating fusion between a lysosome and an endosome that carries the toxin in the cell; locally co-administering a toxin and a lysosome-endosome fusion inhibitor to a group of muscles of the patient in need thereof
12/29/2005US20050287164 Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
12/29/2005US20050287157 Dry formulation for transcutaneous immunization
12/29/2005US20050287139 Wound healing
12/29/2005US20050287135 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
12/29/2005US20050287134 use of a first drug operative to produce local capillary vasodilatation and/or augmented rate of bulk flow which is mixed with a fluid, then delivered subcutaneously or into deeper tissues by use of a hyperdermic needle or infiltration cannula
12/29/2005US20050287119 Treating a superficial interferon-resistant tumor of the bladder by contacting the tumor with Syn 3 and a replication-deficient adenoviral recombinant vector encoding an interferon alpha, where the vector and Syn3 are instilled intravesically; interferon alpha 2b,2a,2 or 1
12/29/2005US20050287097 hydrophobic polymer includes repeating pyrrolidone/alkylene groups containing 10 or more carbon atoms, a hydrophilic polymer including polyacrylic acid, maleic acid-methyl vinyl ether copolymer, starch, cellulose, polyvinyl alcohol, dextrans/yclodextrin; cosmetics; skin
12/29/2005US20050287087 includes an aqueous base of water, methylcellulose and citric acid, pharmaceutically active or cosmetic agent or nutritional agent; drug delivery for treating cardiovascular and psychological disorders, vision defects, inflammation, infections and for cartilage repair and birth control
12/29/2005US20050287081 Pharmaceutically elegant, topical anhydrous aerosol foam
12/29/2005US20050287080 Use of mometasone furoate for treating airway passage and lung disease
12/29/2005US20050287079 Combinations of formoterol and fluticasone propionate for asthma
12/29/2005US20050287078 Minimizing powder retention on surfaces
12/29/2005US20050287077 Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
12/29/2005US20050287076 Compounds for use as surfactants
12/29/2005US20050287075 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant
12/29/2005US20050287070 Ligand-specific opening of a gated-porin channel in the outer membrane of living bacteria
12/29/2005US20050285073 Permanently linked, rigid, magnetic chains
12/29/2005US20050284812 Process for preparing water soluble diterpenes and their applications
12/29/2005US20050284752 Novel electrodes and uses thereof
12/29/2005DE102004027924A1 Arzneiform, enthaltend den Wirkstoff Cholylsarcosin Dosage form comprising the active ingredient cholylsarcosine
12/29/2005CA2814904A1 Apparatus and method for pharmaceutical production
12/29/2005CA2814857A1 Apparatus and method for pharmaceutical production
12/29/2005CA2608862A1 Silk-based drug delivery system
12/29/2005CA2579605A1 Topical compositions and methods for epithelial-related conditions
12/29/2005CA2571679A1 Use of cb2 receptors agonists for the treatment of huntington's disease
12/29/2005CA2570709A1 Solid orally ingestible formulations of tetrodotoxin
12/29/2005CA2570184A1 Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent
12/29/2005CA2570118A1 Enhanced medical product
12/29/2005CA2569968A1 Controlled release matrix pharmaceutical dosage formulation
12/29/2005CA2569964A1 Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
12/29/2005CA2569961A1 Controlled release pharmaceutical formulation
12/29/2005CA2569958A1 Abuse-deterrent drug formulations
12/29/2005CA2569726A1 Hydrophobic ophthalmic compositions and methods of use
12/29/2005CA2569574A1 Minimizing powder retention on surfaces
12/29/2005CA2569570A1 Inhaler using pods
12/29/2005CA2569310A1 Pharmaceutical compositions
12/29/2005CA2568390A1 Polymeric compositions for sustained release of volatile materials
12/29/2005CA2567684A1 Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase
12/29/2005CA2567683A1 Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase
12/29/2005CA2567636A1 Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof
12/29/2005CA2565972A1 Ex-vivo application of solid microparticulate therapeutic agents
12/29/2005CA2564791A1 High pressure spray-dry of bioactive materials
12/29/2005CA2564106A1 Methods to control termites
12/28/2005EP1609856A2 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
12/28/2005EP1609852A1 Bifidobacteria and preparations containing them
12/28/2005EP1609482A1 Drug for treating hemophilia and method of treating hemophilia using the same
12/28/2005EP1609481A1 Injectable pharmaceutical compositions comprising sodium diclofenac, beta-cyclodextrin and a polysorbate
12/28/2005EP1609478A1 Exendin agonist peptide formulations
12/28/2005EP1609477A1 Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure
12/28/2005EP1609474A1 Method for preparing therapeutic agent for cancer
12/28/2005EP1609472A1 Therapeutic agent for hemorrhoidal disease
12/28/2005EP1609470A1 Nasal delivery of apomorphine
12/28/2005EP1609468A2 A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
12/28/2005EP1609466A1 Pharmaceutical compositions and uses thereof in the preparation of a medicament and/or food compostion for the treatment of overweight and/or correlated symptoms in humans and mammalian as well as process of preparation
12/28/2005EP1609465A1 Ophthalmic drug delivery system using polymer micell
12/28/2005EP1609464A1 Intimate hygiene products
12/28/2005EP1608810A2 Disposable, paper-based hospital and operating theater products
12/28/2005EP1608406A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
12/28/2005EP1608403A2 Immunostimulatory nucleic acid oil-in-water formulations for topical application
12/28/2005EP1608385A2 Therapeutic compositions
12/28/2005EP1608383A1 A formulation comprising a bacterial strain
12/28/2005EP1608372A2 Compositions containing fentanyl
12/28/2005EP1608362A1 Stabilized pharmaceutical preparation comprising an amorphous active substance
12/28/2005EP1608359A2 Tumor-targeting drug-loaded particles
12/28/2005EP1608358A1 Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
12/28/2005EP1608353A1 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
12/28/2005EP1608349A1 Oral delivery system comprising an antibacterial and an anti-inflammatory agent
12/28/2005EP1608348A2 Drug delivery systems comprising an encapsulated active ingredient
12/28/2005EP1608347A1 Solid oral dosage form containing seamless microcapsules
12/28/2005EP1608346A1 Alpha-hydroxy acid ester drug delivery compositions and methods of use
12/28/2005EP1608345A1 Capsules with delayed release of the capsule contents for oral administration
12/28/2005EP1608344A2 Oral formulations of cladribine
12/28/2005EP1608343A2 Cladribine formulations for improved oral and transmucosal delivery
12/28/2005EP1608342A2 Stable lamotrigine pharmaceutical compositions and processes for their preparation
12/28/2005EP1608341A1 Water-soluble tablets of metformin
12/28/2005EP1608340A2 A method of preparing gas-filled polymer matrix microparticles useful for delivering drug
12/28/2005EP1608339A1 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
12/28/2005EP1608338A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
12/28/2005EP1608337A2 Combination compositions of camptothecins and fluoropyrimidines
12/28/2005EP1608336A2 Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
12/28/2005EP1608335A1 Controlled release system containing saccharose acetate isobutyrate
1 ... 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 ... 2991